ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
17 announcements
Nath Bio-Genes (India) Ltd held its 33rd AGM on September 24, 2026. Shareholders approved all five resolutions, including a final dividend of ₹2/- per share.
Nath Bio-Genes (India) Ltd issued notice for its 33rd Annual General Meeting, to be held on September 24, 2026, alongside the Annual Report for FY2025-26.
SEBI has initiated a forensic audit of Nath Bio-Genes (India) Ltd for financial years 2020-21 to 2025-26. CNK & Associates LLP has been appointed as the forensic auditor.
Nath Bio-Genes reported strong Q1 FY27 results with Revenue and EBITDA growing 15% and 17% YoY respectively. The company continues to focus on high-yield cotton, maize, and paddy seeds.
Nath Bio-Genes (India) Ltd reported revenue from operations of ₹328.4 Cr (+15.8% YoY) and net profit of ₹32.3 Cr (+14.1% YoY) for Q1 FY27.
Nath Bio-Genes (India) Ltd filed its quarterly shareholding pattern under Regulation 31(1)(b). This disclosure provides the updated distribution of shareholding across various investor categories.
Nath Bio-Genes (India) Ltd has scheduled a board meeting for 29th July 2026 to consider and approve its unaudited financial results for the June quarter.
Nath Bio-Genes (India) Limited submitted its Annual Secretarial Compliance Report for the financial year 2025-26. The auditor reported nil non-compliance, confirming the company's strong governance standards.
Nath Bio-Genes reported FY26 revenue of ₹4,316M (up 19% YoY) with an EBITDA of ₹525M. Management is diversifying into non-cotton, non-paddy segments (NCD) and international markets like Uzbekistan.
Nath Bio-Genes (India) Ltd confirmed it is not a Large Corporate under SEBI norms. The company reported zero outstanding long-term borrowings as of March 2026.
Nath Bio-Genes reported strong FY26 performance with 19% revenue growth and international expansion into Uzbekistan. Strategy focused on core Cotton/Paddy crops and premium seed varieties.
Nath Bio-Genes reported FY26 revenue of ₹4,316 Mn, a 19% YoY increase, driven by strong growth in Cotton, Paddy, and Maize segments. Strategy focuses on R&D, product diversification, and international expansion.
Nath Bio-Genes (India) Limited announced board approval for the re-appointment of Mr. Hitesh Rajnikant Purohit as an Independent Director for a five-year term. Additionally, M/s. K.P. Sahasrabudhe and Co was appointed as the Internal Auditor for a 12-month tenure starting May 4, 2026.
Nath Bio-Genes (India) Ltd reported revenue from operations of ₹51.6 Cr (-0.6% YoY) and net profit of ₹0 Cr for Q4 FY26.
Nath Bio-Genes (India) Ltd reported consolidated annual revenue of ₹445.10 Crore for FY26. The Board recommended a dividend of ₹2 per share (20%) and approved the reappointment of Mr. Hitesh Rajnikant Purohit as an Independent Director for a second five-year term starting March 2027.
Nath Bio-Genes (India) Limited has scheduled a board meeting on May 4, 2026, to consider audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The board will also consider recommending a final dividend for the financial year. The trading window remains closed until May 6, 2026.
Nath Bio-Genes (India) Ltd will hold a Board Meeting on May 4, 2026. The board will consider audited financial results for Q4 and FY26, alongside a dividend recommendation for 2025-26. The trading window remains closed until May 6, 2026.